Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ironwood Earns $15M Astellas Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ironwood Earns $15M Astellas Milestone

Enrolls first patient in Phase III linaclotide trial

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ironwood Pharmaceuticals, Inc. has earned a $15 million development milestone payment from partner Astellas Pharma triggered by Astellas’ enrollment of the first patient in a Phase III trial of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C) in Japan. Astellas expects to complete this trial in 2016.
 
The companies entered a licensing agreement in 2009 to develop and commercialize linaclotide in Japan for the treatment of IBS-C, chronic constipation and other gastrointestinal conditions. Ironwood received $30 million upfront and is eligible to receive an additional $30 million in development milestones, consisting of $15 million upon regulatory filing in Japan and $15 million upon approval. The agreement also provides for Ironwood to receive royalties on sales.
 
Also, Astellas plans to expand its development of linaclotide in Japan and is beginning a Phase II trial in adults with chronic constipation. If approved, the same royalty terms would apply.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics